Palvella Therapeutics PVLA Payment for Contingent Consideration Liability, Financing Activities

Payment for Contingent Consideration Liability, Financing Activities at other companies

ePlusPLUS

$0—

AvePoint, Inc.AVPT

$0-100%

The Baldwin Insurance Group, Inc.BWIN

$0-100%

TFX

TeleflexTFX

$58K+3.6%

Henry ScheinHSIC

$0-100%

Energy FuelsUUUU

$0-100%

Other financials

Income statement

See full

Revenue$53.0K-97.3%

Operating income-$14.9M-88.7%

Net income-$15.8M-92.6%

EPS (diluted)-$1.20-62.2%

Balance sheet

See full

Cash & equivalents$206.4M+173%

Total debt$584.0K—

Total equity$232.3M+318%

Total assets$263.8M+232%

Cash flow

See full

Operating cash flow-$10.9M-60.5%

CapEx--100%

Free cash flow-$2.7M+72.0%

Valuation

See full

Market cap$1.86B+468%

Profitability

See full

Operating margin-183.2%-13.5pp

Net margin71.7%+40.4pp

FCF margin-99.8%-34.2pp

Returns & leverage

See full

Return on equity-34.2%—

Debt / equity0×—

Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's payment for contingent consideration liability, financing activities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Palvella Therapeutics's payment for contingent consideration liability, financing activities?: Palvella Therapeutics (PVLA) reported payment for contingent consideration liability, financing activities of $1.98M in Q1 2026.